Cardiokol

Voice-based Markers for Large-scale Monitoring and Screening of Heart Rhythm Disorders

Health Tech & Life Sciences
Private
Follow

Company Overview

Snapshot

Founded in August 2017 by Alon Goren, Eli Attar, and Pini Sabach, Cardiokol operates with 1–10 employees. The company has raised $8M across two funding rounds from two investors, with Kamet Ventures identified as a lead investor. In November 2021, Cardiokol was selected to join Bayer's G4A program, signaling strategic validation in the digital health sector.

Business overview

Cardiokol is a digital telehealth company focused on developing voice-based markers and methods for the large-scale monitoring and screening of heart rhythm disorders. The company leverages proprietary technology, implemented across various speech platforms including landlines, smartphones, smart speakers, and voice assistants. Cardiokol provides low-cost, long-term, and user-friendly monitoring solutions primarily targeting at-risk populations of older adults (65+) in the United States and Europe, operating within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Patient Remote Monitoring.

Strategic signal

In November 2021, Cardiokol was selected as one of nine digital health pioneers to join Bayer's G4A program. This inclusion signifies a strong validation of Cardiokol's innovative approach to heart rhythm disorder screening and monitoring, indicating potential for accelerated development and market penetration through strategic partnerships with established pharmaceutical and healthcare entities.

Log in to access full profile

Company Intelligence Q&A

When was Cardiokol founded and by whom?
Cardiokol was founded in August 2017 by Alon Goren, Eli Attar, and Pini Sabach.
What is Cardiokol's primary focus?
Cardiokol focuses on developing voice-based markers and methods for monitoring and screening heart rhythm disorders in large at-risk populations, particularly older adults.
What significant program did Cardiokol join in 2021?
In November 2021, Cardiokol joined Bayer's G4A program as one of nine digital health pioneers.
How much capital has Cardiokol raised?
Cardiokol has raised $8M in total funding across two rounds.
Which investors participated in Cardiokol's funding rounds?
Cardiokol has received funding from investors including Kamet Ventures and KYTO.
Log in to access full profile